Key Resources

Instructions for Use
Features & Benefits
Osteogenic1
Contains viable, lineage committed bone cells that areable to proliferate in vitro post cryopreservation and thaw4
Osteoconductive1
Contains corticocancellous chips that provide a naturalscaffold for cell attachment, cell migration and cellproliferation1
Osteoinductive1
Demineralization of the cortical bone exposes thenatural growth factors within the matrix1
Safety
Every lot is aseptically processed and tested for sterilityusing USP <71>1
Packaging
The rapid heat transfer not only allows for all sizes tothaw in less than 5 minutes, but is also vital for cellviability5
Processing Time
ViviGen reaches cryopreservation within 72 hours maximizing cell viability 24 hours sooner than competitive products1
Maximized Cell Viability
The processing of ViviGen is focused on protecting viable, lineage committed bone cells from recovery to implantation1
Multiple Forms
ViviGen and ViviGen Formable provide a comprehensive solution to meet surgeons’ clinical needs
Supporting Documentation
Resources
-
ViviGen Clinical Compendium
-
ViviGen®/ViviGen Formable® Sell Sheet- TRAUMA
-
Select all documents (2)
Specifications
BL-1500-001 | 1cc | |
---|---|---|
BL-1500-002 | 5cc | |
BL-1500-003 | 10cc | |
BL-1500-004 | 15cc | |
BL-1600-001 | Small | |
BL-1600-002 | Medium | |
BL-1600-003 | Large | |
BL-1600-004 | X-Large |
References
- LifeNet Health Data on File DHF 12-008, DHF 15-001, CC#52268.
- Reichert et al. Ovine coritical osteoblasts outperformbone marrow cells in an ectopic bone assy. J Tissue EngRegen Med 2011; 5:831-844.
- Tortelli, et al. The development of tissue-engineeredbone of different origin through endochondral andintramembranous ossification following the implantationof mesenchymal stem cells and osteoblasts in a murinemodel. Biomaterials 2010; 31:242-249.
- Sachs, Chen. Osteogenic Potential of the ViviGen CellularComponent Results from In Vitro Studies.
- Chen. Advantage of ViviGen Packaging Results from InVitro Studies.
- 68-20-210: K. Apostle, “Surgical Repair of Open FemurFracture with Bone Loss Using ViviGen® Cellular BoneMatrix”, 2018.
- 68-20-224: A. Kaz, “Surgical Repair of a Tibial Metaphysial Defect Using ViviGen Formable® CellularBone Matrix”, 2019.
- 68-20-226: A. Kaz, “Surgical Repair of Severe Varus Ankle Deformity with Osteoarthritis Using ViviGenCellular Bone Matrix”, 2019.
- 68-20-227: A. Kaz, “Surgical Repair of a Nonunion Fracture at the Fifth Metatarsal Using ViviGen CellularBone Matrix”, 2019.
- 10. 68-20-237: W. Giessler, “Surgical Repair of a Delayed Union to the Radius Diaphysis Using ViviGen® CellularBone Matrix in a Division I Football Athlete”, 2019.
- 68-20-238: W. Giessler, “Salvage of Failed Wrist Arthroplasty Using ViviGen® Cellular Bone Matrix”, 2019.
ViviGen & ViviGen Formable are registered trademarks of LifeNet Health.
Indication Statement
ViviGen is intended for repair or reconstruction of musculoskeletal defects.
120443-190808 DSUS
© DePuy Synthes 2022. All Rights Reserved. This site is published by the DePuy Synthes Companies, which are solely responsible for its content. This site is governed solely by applicable U.S. laws and governmental regulations. This site is for visitors from the United States. The third party trademarks used herein are the trademarks of their respective owners.